September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Non-penetrating deep sclerectomy for the management of severe glaucoma
Author Affiliations & Notes
  • IGOR LELEU
    unit 2, quinze vingts hospital, PARIS, France
  • Benjamin Penaud
    unit 2, quinze vingts hospital, PARIS, France
  • Esther Blumen-Ohana
    unit 2, quinze vingts hospital, PARIS, France
  • Thibault Rodallec
    unit 2, quinze vingts hospital, PARIS, France
  • raphael ADAM
    unit 2, quinze vingts hospital, PARIS, France
  • Oliver LAPLACE
    unit 2, quinze vingts hospital, PARIS, France
  • Jad AKESBI
    unit 2, quinze vingts hospital, PARIS, France
  • Jean-Philippe NORDMANN
    unit 2, quinze vingts hospital, PARIS, France
  • Footnotes
    Commercial Relationships   IGOR LELEU, None; Benjamin Penaud, None; Esther Blumen-Ohana, None; Thibault Rodallec, None; raphael ADAM, None; Oliver LAPLACE, None; Jad AKESBI, None; Jean-Philippe NORDMANN, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6514. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      IGOR LELEU, Benjamin Penaud, Esther Blumen-Ohana, Thibault Rodallec, raphael ADAM, Oliver LAPLACE, Jad AKESBI, Jean-Philippe NORDMANN; Non-penetrating deep sclerectomy for the management of severe glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6514.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Report our medium-term outcomes of non-penetrating deep sclerectomy (NPDS) for severe glaucoma treatment. To date, a limited number of studies have specifically explored non-penetrating filtration surgery in this population.

Methods : We analyzed retrospectively 76 eyes of 69 patients after a NPSD with mitomycine C between 2009 and 2015, with or without a phaco-émulsification. All patients had a severe glaucoma (mean deviation (MD) <-20 dB on the preoperative visual field according to Glaucoma Staging System based on Humphrey visual field) progressing despite a maximal medical treatment.

Results : Of the 76 eyes, we included 65 open-angle glaucoma, 3 juvenile glaucoma, 1 normal pressure glaucoma and 7 secondary glaucoma. 21 eyes had a combined surgery and 10 was already pseudophakic.The average follow-up was 21 months (min:1; max :72) and 54 eyes was followed more than 1 year. 37 eyes were in the end-stage glaucoma (MD<-30dB ou unquantifiable). The mean age of the patients was 57 years (from 33 to 86). Before surgery, the average intraocular pressure (IOP) was 21;8 mmHg, the MD was -23.5dB, the VFI 23%. The IOP, 1 year (54 eyes), 2 years (42 eyes) and 3 years after surgery was de 13.9 (-8.1mmHg reduction, P<0.001) , 14.1 et 14.2mmHg ((p<0.001) respectively. During the folllow-up, 8 patients (10,5%) had to undergo new filtration surgery. A goniopuncture has been done on 35 eyes (45%) with an average delay of 7 months. After 1 year, the number of anti-glaucomatous molecules has been reduced from an average of 3.0 before surgery to 0.5 after surgery (86,5% of reduction, p<0.001). The postoperative visual field was comparable with the preoperative (postoperative MD was -25.48 dB (reduction of -0.13dB, p=0.9)). Regarding per-operative complications, we observed 3 perforations in need of perforating trabeculectomy and 9 microperforations. Immediate postoperative complications were the occurrence of 2 iris incarcerations, 2 hypotonia with choroïdal detachment, 1 hypertonia that required one goniopuncture and 4 conjunctival seidel.
None of the eyes developed a loss of central vision.

Conclusions : Severe glaucoma impose a low target intraocular pressure that required frequently filtration surgery. In the medium term, the non-penetrating deep sclerectomy produce good results in terms of pressure control and stability of viual field, even in the most severe glaucoma, while offering a high level of safety especially in the oss of central vision.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×